“It is not an accident that OmniComm continues to grow and prosper in these challenging economic times,” said Stephen Johnson, COO of OmniComm. “We work hard to be in tune with our customers’ needs and we are steadfast in our commitment to delivering an excellent product backed by even better customer service. We are flattered by the commitment that our customers have shown to us but we must not become complacent if we are going to live up to their expectations.”
Thomas Wells, Vice President of Technology for OmniComm added, “Our customers are becoming EDC experts and expect much more than just the typical data collection and cleaning. Business intelligence and integration with external applications for better data handling have become necessities for our customers to meet the challenges of their expedited clinical timelines. OmniComm’s vision for early 2009 includes the creation of a Centralized Data Hub where eClinical services can be seamlessly integrated with our client’s systems and repositories. This solution will empower our clients to take control of their data and better leverage core industry standards like CDISC/CDASH and STDM."
OmniComm continues to increase its customer base with a strong mix of new customer business coupled with steady, recurring business from its existing loyal customers. The following is a breakdown of new business for Q3, 2008.
Q3 New Contracts 2008:
Industry leading academic research center and best-in-class contract research organization choose OmniComm for Technology Transitions to bring TrialMaster in-house.
Biotechnology
• 5 month, Phase I, HIV study with 1 site and 44 subjects
• 13 month, Phase IB, infectious disease study with 12 sites and 24 subjects
• 4 month, Phase IV, HIV study with 30 sites and 160 subjects
• 5 month, Phase I, infectious disease study with 1 site and 15 subjects
• 24 month, Phase IV, hepatitis B study with 15 sites and 30 subjects
• 9 month, Phase I, infectious disease study with 1 site and 40 subjects
Contract Research Organizations
• 30 month, Phase II, oncology study with 45 sites and 160 subjects
• 24 month, Phase II oncology study with 8 sites and subjects TBD
• 6 month, Phase II, dermatology study with 25 sites and 200 subjects
• 18 month, Phase II, cardiovascular study with 55 sites and 360 subjects
Medical Device
• 15 month, study with 20 sites and 1000 subjects
• 60 month, study with 28 sites and 225 subjects
Academic
• 18 month, Phase III, cardiovascular study with 10 sites and 60 subjects
• 6 month, Phase I, oncology study with 25 sites and 172 subjects
About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm’s growing base of satisfied customers is a direct result of the company’s commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm’s client intuitive pricing model allows companies that range from small, to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn, Chicago, Germany, Tula, Russia, California, Maryland, New York, North Carolina and Texas.
Safe Harbor Disclaimer
Statements about OmniComm’s future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm’s operations, markets and profitability, actual results could differ materially and adversely from the expected results.
